Hafize Emine Sönmez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6791237/publications.pdf

Version: 2024-02-01

		759233	713466
50	605	12	21
papers	citations	h-index	g-index
51	51	51	806
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Quantitative analysis of preclinical ocular microvascular changes in Multisystemic Inflammatory Syndrome in Children (MIS-C) detected by optical coherence tomography angiography. Eye, 2023, 37, 566-573.	2.1	2
2	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
3	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatology International, 2022, 42, 469-475.	3.0	16
4	Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy, 2022, 22, 197-202.	3.1	5
5	Optical coherence tomography angiography of subclinical ocular features in pediatric Behçet disease. Journal of AAPOS, 2022, 26, 24.e1-24.e6.	0.3	6
6	Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. Vaccine, 2022, 40, 1829-1836.	3.8	7
7	Editorial: Hereditary Periodic Fevers and Autoinflammatory Diseases. Frontiers in Pediatrics, 2022, 10, 855738.	1.9	1
8	The Multifaceted Presentation of the Multisystem Inflammatory Syndrome in Children: Data from a Cluster Analysis. Journal of Clinical Medicine, 2022, 11, 1742.	2.4	6
9	CXCL10/IP10 as a Biomarker Linking Multisystem Inflammatory Syndrome and Left Ventricular Dysfunction in Children with SARS-CoV-2. Journal of Clinical Medicine, 2022, 11, 1416.	2.4	6
10	Is it all about age? Clinical characteristics of Kawasaki disease in the extremely young: PeRA research group experience. Postgraduate Medicine, 2022, 134, 429-434.	2.0	2
11	Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars. BioDrugs, 2022, , 1.	4.6	O
12	Cluster Analysis of Pediatric Behçet's Disease: Data from The Pediatric Rheumatology Academy (PeRA)-Research Group (RG). Modern Rheumatology, 2022, , .	1.8	3
13	Preclinical ocular microvascular changes in juvenile dermatomyositis: A pilot optical coherence tomography angiography study. Microvascular Research, 2022, 143, 104382.	2.5	2
14	Comorbidities and phenotype–genotype correlation in children with familial Mediterranean fever. Rheumatology International, 2021, 41, 113-120.	3.0	30
15	Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clinical Rheumatology, 2021, 40, 2327-2337.	2.2	9
16	Systemic lupus erythematosus complicated with Castleman disease: a case-based review. Rheumatology International, 2021, 41, 475-479.	3.0	11
17	Response to †How to define disease severity accurately in patients with familial Mediterranean fever'. Rheumatology International, 2021, 41, 239-240.	3.0	O
18	The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods. Journal of Clinical Rheumatology, 2021, 27, 1-4.	0.9	9

#	Article	IF	CITATIONS
19	The readiness of pediatric rheumatology patients and their parents to transition to adultâ€oriented treatment. International Journal of Rheumatic Diseases, 2021, 24, 397-401.	1.9	7
20	Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey. Rheumatology International, 2021, , 1.	3.0	4
21	Neuroimaging of Children With Takayasu Arteritis. Journal of Child Neurology, 2021, 36, 642-647.	1.4	2
22	Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis. Rheumatology International, 2021, , 1.	3.0	1
23	Comment on: Clinical significance of E148Q heterozygous variant in paediatric Familial Mediterranean Fever. Rheumatology, 2021, 60, e294-e295.	1.9	1
24	Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience. Rheumatology International, $2021, 1.$	3.0	4
25	Multisystemic inflammatory syndrome in children associated with COVID-19: a single center experience in Turkey. Turkish Archives of Pediatrics, 2021, 56, 192-199.	0.4	16
26	Sacroiliitis in children and adolescents with familial Mediterranean fever. Advances in Rheumatology, 2021, 61, 29.	1.7	4
27	Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatric Rheumatology, 2021, 19, 134.	2.1	15
28	Comparison of Pediatric Familial Mediterranean Fever Patients Carrying Only E148Q Variant With the Ones Carrying Homozygous Pathogenic Mutations. Journal of Clinical Rheumatology, 2021, 27, 182-186.	0.9	7
29	Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus, 2021, 30, 2144-2150.	1.6	9
30	Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort. Frontiers in Pediatrics, 2021, 9, 805919.	1.9	22
31	A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. Journal of Rheumatology, 2020, 47, 117-125.	2.0	65
32	Profile of new referrals to a single pediatric rheumatology center in Turkey. Rheumatology International, 2020, 40, 313-321.	3.0	9
33	Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center. Rheumatology International, 2020, 40, 21-27.	3.0	17
34	Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatology International, 2020, 40, 771-776.	3.0	5
35	Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19. Rheumatology International, 2020, 40, 1613-1623.	3.0	32
36	Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatology International, 2020, 40, 1111-1116.	3.0	8

#	Article	IF	CITATIONS
37	Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clinical Rheumatology, 2020, 39, 3733-3745.	2.2	9
38	Rheumatic diseases in Syrian refugee children: a retrospective multicentric study in Turkey. Rheumatology International, 2020, 40, 583-589.	3.0	7
39	Time to collaborate: Objectives, Design, and Methodology of PeRA-Research Group. İstanbul Kuzey Klinikleri, 2020, 8, 200-202.	0.3	6
40	The factors affecting the disease course in Kawasaki disease. Rheumatology International, 2019, 39, 1343-1349.	3.0	11
41	Comment on: Tofacitinib for familial Mediterranean fever: a new alternative therapy?. Rheumatology, 2019, 58, 923-923.	1.9	0
42	The clinical spectrum of Henoch–Schönlein purpura in children: a single-center study. Clinical Rheumatology, 2019, 38, 1707-1714.	2,2	30
43	AB1041â€PREVALENCE OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBGROUPS AND JIA-ASSOCIATED UVEITIS AMONG JIA PATIENTS ADMITTED TO REFERRAL PEDIATRIC RHEUMATOLOGY CLINICS IN TURKEY: A RETROSPECTIVE STUDY, JUPITER. , 2019, , .		0
44	Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Multiple Sclerosis and Related Disorders, 2019, 27, 20-22.	2.0	4
45	Polyarteritis nodosa: lessons from 25 years of experience. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 52-56.	0.8	9
46	Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clinical Rheumatology, 2018, 37, 3329-3335.	2.2	97
47	Increased psoriasis frequency in patients with familial Mediterranean fever. Upsala Journal of Medical Sciences, 2018, 123, 57-61.	0.9	11
48	Pediatric forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 137-147.	3.3	11
49	A clinical update on inflammasomopathies. International Immunology, 2017, 29, 393-400.	4.0	20
50	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. Current Rheumatology Reports, 2016, 18, 8.	4.7	12